Sebaceous carcinoma: evidence-based clinical practice guidelines

Joshua L. Owen, Nour Kibbi, Brandon Worley, Ryan C. Kelm, Jordan V. Wang, Christopher A. Barker, Ramona Behshad, Christopher K. Bichakjian, Diana Bolotin, Jeremy S. Bordeaux, Scott H. Bradshaw, Todd V. Cartee, Sunandana Chandra, Nancy L. Cho, Jennifer N. Choi, M. Laurin Council, Hakan Demirci, Daniel B. Eisen, Bita Esmaeli, Nicholas GoldaConway C. Huang, Sherrif F. Ibrahim, S. Brian Jiang, John Kim, Timothy M. Kuzel, Stephen Y. Lai, Naomi Lawrence, Erica H. Lee, Justin J. Leitenberger, Ian A. Maher, Margaret W. Mann, Kira Minkis, Bharat B. Mittal, Kishwer S. Nehal, Isaac M. Neuhaus, David M. Ozog, Brian Petersen, Veronica Rotemberg, Sandeep Samant, Faramarz H. Samie, Sabah Servaes, Carol L. Shields, Thuzar M. Shin, Joseph F. Sobanko, Ally Khan Somani, William G. Stebbins, J. Regan Thomas, Valencia D. Thomas, David T. Tse, Abigail H. Waldman, Michael K. Wong, Y. Gloria Xu, Siegrid S. Yu, Nathalie C. Zeitouni, Timothy Ramsay, Kelly A. Reynolds, Emily Poon, Murad Alam

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Sebaceous carcinoma usually occurs in adults older than 60 years, on the eyelid, head and neck, and trunk. In this Review, we present clinical care recommendations for sebaceous carcinoma, which were developed as a result of an expert panel evaluation of the findings of a systematic review. Key conclusions were drawn and recommendations made for diagnosis, first-line treatment, radiotherapy, and post-treatment care. For diagnosis, we concluded that deep biopsy is often required; furthermore, differential diagnoses that mimic the condition can be excluded with special histological stains. For treatment, the recommended first-line therapy is surgical removal, followed by margin assessment of the peripheral and deep tissue edges; conjunctival mapping biopsies can facilitate surgical planning. Radiotherapy can be considered for cases with nerve or lymph node involvement, and as the primary treatment in patients who are ineligible for surgery. Post-treatment clinical examination should occur every 6 months for at least 3 years. No specific systemic therapies for advanced disease can be recommended, but targeted therapies and immunotherapies are being developed.

Original languageEnglish
Pages (from-to)e699-e714
JournalThe Lancet Oncology
Volume20
Issue number12
DOIs
StatePublished - Dec 2019

Fingerprint Dive into the research topics of 'Sebaceous carcinoma: evidence-based clinical practice guidelines'. Together they form a unique fingerprint.

Cite this